Imaging of Cognition, Learning, and Memory in Aging
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01297114|
Recruitment Status : Completed
First Posted : February 16, 2011
Last Update Posted : November 1, 2017
|Condition or disease||Intervention/treatment|
|Alzheimer's Disease||Drug: Florbetaben|
The basic approach to measuring the brain activity associated with a given cognitive process (or processes) is as follows: It is known that increases in brain neuronal activity are associated with local increases in energy metabolism. Under normal circumstances, increases in brain metabolism lead to local changes in blood oxygenation in venules and larger veins. This change in blood oxygenation can be detected imaging methods which are sensitive to the differences in magnetic state between oxygenated and deoxygenated hemoglobin.
The ultimate benefit of this research is to better understand how changes in both performance and the brain organization underlying that performance are affected by aging.
|Study Type :||Observational|
|Actual Enrollment :||294 participants|
|Official Title:||Imaging of Cognition, Learning, and Memory in Aging|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||October 1, 2017|
|Actual Study Completion Date :||October 1, 2017|
Participants aged 60-70
Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
Other Name: F-18 BAY
Participants aged 20-30
Younger participants will not undergo PET scanning that will be studied with other methods.
- Cognition as measured with cognitive evaluations [ Time Frame: cross sectional ]We will assess the relationship between the presence of amyloid and cognition as measured with standard cognitive and neuropsychological tests
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01297114
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10032|
|Principal Investigator:||Yaakov Stern, PhD||Columbia University|